Sino Biological is a world-leading manufacturer of recombinant protein and antibody reagents for life science researches and drug discoveries. In response to the current COVID-19 pandemic, we have developed a series of active reagents (virus proteins, antibodies, and pseudoviruses) to facilitate serologic tests and anti-viral drug developments.
Dewpoint Therapeutics raise $77m in Series B financing
Latest NewsA $77 Series B financing allows Dewpoint Therapeutics Inc to select a lead programme from its new drug class of molecular condensates and push proof-of-concept studies.
Kurma Partners close diagnostics fund at €50m
Latest NewsThe only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at €50m.
Danish Galecto Inc. secures US$64m equity financing
Latest NewsDanish fibrosis and cancer specialist Galecto Inc. has raised US$64m in a Series B round led by Soleus Capital.
MosaMeat NV bags US$55m financing
Latest NewsMaastricht-based cultured meat producer Mosa Meat NV has raised $55m in a Series B financing, bringing its funding to $63.8m.
Green carbon footprint
OpinionIn September, Unilever announced a €1bn investment to improve the sustainability of its cleaning brands from the ground up. European Biotechnology spoke to Dr Neil Parry, R&D programme director of biotechnology and biosourcing at Unilever about the goals of Clean Future.
A Comprehensive Tool Set for COVID-19 Research
Sponsored PublicationsSino Biological is a world-leading manufacturer of recombinant protein and antibody reagents for life science researches and drug discoveries. In response to the current COVID-19 pandemic, we have developed a series of active reagents (virus proteins, antibodies, and pseudoviruses) to facilitate serologic tests and anti-viral drug developments.
New on Vifor Pharma board
AppointmentsSince September Gregory Oakes is a new Member of the Vifor Management Board and President North America of the Swiss pharmaceutical company.
Pureos Bioventures closes US$170m fund
Latest NewsNewly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers.
Biotechs request money for COVID therapeutics
Latest NewsGerman biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies.
Complete toolkit for SARS-CoV-2 antigen test
ProductsSino Biological Inc. has developed a complete toolkit for SARS-CoV-2 antigen tests, including a large panel of antibodies specific to SARS-CoV-2 S&N proteins and antibody pairs that can be used to assemble detection assays for the corresponding antigen.